Stem Cell Reports (Oct 2016)
Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency
- Alvaro Muñoz-López,
- Damià Romero-Moya,
- Cristina Prieto,
- Verónica Ramos-Mejía,
- Antonio Agraz-Doblas,
- Ignacio Varela,
- Marcus Buschbeck,
- Anna Palau,
- Xonia Carvajal-Vergara,
- Alessandra Giorgetti,
- Anthony Ford,
- Majlinda Lako,
- Isabel Granada,
- Neus Ruiz-Xivillé,
- Sandra Rodríguez-Perales,
- Raul Torres-Ruíz,
- Ronald W. Stam,
- Jose Luis Fuster,
- Mario F. Fraga,
- Mahito Nakanishi,
- Gianni Cazzaniga,
- Michela Bardini,
- Isabel Cobo,
- Gustavo F. Bayon,
- Agustin F. Fernandez,
- Clara Bueno,
- Pablo Menendez
Affiliations
- Alvaro Muñoz-López
- Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Casanova 143, 08036 Barcelona, Spain
- Damià Romero-Moya
- Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Casanova 143, 08036 Barcelona, Spain
- Cristina Prieto
- Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Casanova 143, 08036 Barcelona, Spain
- Verónica Ramos-Mejía
- Genomic Oncology Department, Centre for Genomics and Oncology GENyO, 18016 Granada, Spain
- Antonio Agraz-Doblas
- Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Casanova 143, 08036 Barcelona, Spain
- Ignacio Varela
- IBBTEC, CSIC-University of Cantabria, 39011 Santander, Spain
- Marcus Buschbeck
- Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Casanova 143, 08036 Barcelona, Spain
- Anna Palau
- Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Casanova 143, 08036 Barcelona, Spain
- Xonia Carvajal-Vergara
- Cell Therapy Department, Centro de Investigación Médica Aplicada (CIMA), 31008 Pamplona, Spain
- Alessandra Giorgetti
- Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Casanova 143, 08036 Barcelona, Spain
- Anthony Ford
- Centre for Evolution and Cancer, Institute of Cancer Research, London SW7 3RP, UK
- Majlinda Lako
- Institute of Genetic Medicine, Newcastle University, Newcastle NE1 7RU, UK
- Isabel Granada
- Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Casanova 143, 08036 Barcelona, Spain
- Neus Ruiz-Xivillé
- Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Casanova 143, 08036 Barcelona, Spain
- Sandra Rodríguez-Perales
- Cytogenetics Group, Centro Nacional de Investigaciones Oncológicas (CNIO), 28029 Madrid, Spain
- Raul Torres-Ruíz
- Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Casanova 143, 08036 Barcelona, Spain
- Ronald W. Stam
- Department of Pediatric Oncology/Hematology, Erasmus Medical Center, Erasmus University, 3015 CN Rotterdam, the Netherlands
- Jose Luis Fuster
- Department of Pediatric Oncohematology, Clinical University Hospital Virgen de la Arrixaca, 30120 Murcia, Spain
- Mario F. Fraga
- Cancer Epigenetics Laboratory, Instituto Universitario de Oncología del Principado de Asturias (IUOPA-HUCA), Universidad de Oviedo, 33003 Oviedo, Spain
- Mahito Nakanishi
- Research Center for Stem Cell Engineering, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraka 305-0046, Japan
- Gianni Cazzaniga
- University di Milano-Bicocca, Ospedale San Gerardo/Fondazione MBBM, 20052 Monza MB, Italy
- Michela Bardini
- University di Milano-Bicocca, Ospedale San Gerardo/Fondazione MBBM, 20052 Monza MB, Italy
- Isabel Cobo
- Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Casanova 143, 08036 Barcelona, Spain
- Gustavo F. Bayon
- Cancer Epigenetics Laboratory, Instituto Universitario de Oncología del Principado de Asturias (IUOPA-HUCA), Universidad de Oviedo, 33003 Oviedo, Spain
- Agustin F. Fernandez
- Cancer Epigenetics Laboratory, Instituto Universitario de Oncología del Principado de Asturias (IUOPA-HUCA), Universidad de Oviedo, 33003 Oviedo, Spain
- Clara Bueno
- Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Casanova 143, 08036 Barcelona, Spain
- Pablo Menendez
- Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Casanova 143, 08036 Barcelona, Spain
- DOI
- https://doi.org/10.1016/j.stemcr.2016.08.013
- Journal volume & issue
-
Vol. 7,
no. 4
pp. 602 – 618
Abstract
Induced pluripotent stem cells (iPSCs) are a powerful tool for disease modeling. They are routinely generated from healthy donors and patients from multiple cell types at different developmental stages. However, reprogramming leukemias is an extremely inefficient process. Few studies generated iPSCs from primary chronic myeloid leukemias, but iPSC generation from acute myeloid or lymphoid leukemias (ALL) has not been achieved. We attempted to generate iPSCs from different subtypes of B-ALL to address the developmental impact of leukemic fusion genes. OKSM(L)-expressing mono/polycistronic-, retroviral/lentiviral/episomal-, and Sendai virus vector-based reprogramming strategies failed to render iPSCs in vitro and in vivo. Addition of transcriptomic-epigenetic reprogramming “boosters” also failed to generate iPSCs from B cell blasts and B-ALL lines, and when iPSCs emerged they lacked leukemic fusion genes, demonstrating non-leukemic myeloid origin. Conversely, MLL-AF4-overexpressing hematopoietic stem cells/B progenitors were successfully reprogrammed, indicating that B cell origin and leukemic fusion gene were not reprogramming barriers. Global transcriptome/DNA methylome profiling suggested a developmental/differentiation refractoriness of MLL-rearranged B-ALL to reprogramming into pluripotency.
Keywords